Single-Class Therapy for HIV is Not Optimal Care

Centers for Disease Control and Prevention. HIV/AIDS Surveillance Report 2002;14: TableA1-A4 (December 2002 addendum). www.cdc.gov/hiv/stats/hasrlink.htm (accessed 2004 Jan 14).

Centers for Disease Control and Prevention. HIV/AIDS Surveillance Report 2002;14:10. www.cdc.gov/hiv/stats/hasrlink.htm (accessed 2004 May 26).

Fauci AS Bartlett JG , Co-Chairs. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services and Kaiser Family Foundation panel recommendations. November 10, 2003. www.aidsinfo.nih.gov (accessed 2004 May 26).

Porter K Babiker A Bhaskaran K Darbyshire J Pezzotti P Porter K Determinants of survival following HIV-1 seroconversion after the introduction of HAART. Lancet 2003;362:1267–74.

Toole J. Dear Doctor letter: high rate of virologic failure in patients with HIV infection treated with once-daily administered triple NRTI regimen containing didanosine, lamivudine, and tenofovir. Foster City, CA: Gilead Sciences, October 14, 2003.

Farthing C Khanlou H Yeh V. Early virologic failure in a pilot study evaluating the efficacy of once daily abacavir (ABC), lamivudine (3TC), and tenofovir DF (TDF) in treatment naïve HIV-infected patients (oral presentation). Presented at: 2nd International AIDS Society conference on HIV Pathogenesis and Treatment, Paris, July 13–16, 2003.

Gallant JE Rodriguez A Weinberg W. Early non-response to tenofovir DF (TDF) + abacavir (ABC) and lamivudine (3TC) in a randomized trial compared to efavirenz (EFV) + ABC and 3TC: ESS30009 unplanned interim analysis (abstract H-1722a). Presented at: 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, September 14–17, 2003.

Gerstoff J Kirk O Obel N Pederson C Mathieson L Nielsen H Low efficacy and high frequency of adverse events in a randomized trial of triple nucleoside regimen abacavir, stavudine and didanosine. AIDS 2003;17:2045–52.

Gulick RM Ribaudo HJ Shikman CM. ACTG 3095: a comparative study of 3 protease inhibitor-sparing regimens for the initial treatment of HIV infection (abstract 41). Presented at: 2nd International AIDS Society Conference on HIV Pathogenesis and Treatment, Paris, July 13–16, 2003.

van Leeuwen R Katlama C Murphy RL Squires K Gatell J Horban A A randomized trial to study first-line combination therapy with or without a protease inhibitor in HIV-1—infected patients. AIDS 2003;17:987–99.

Package insert. Trizivir (zidovudine/lamivudine/abacavir sulfate). Research Triangle Park, NC: GlaxoSmithKline, August 2002.

Package insert. Emtriva (emtricitabine). Foster City, CA: Gilead Sciences, July 2003.

Sanne I Anderson J Kargl D Sorbell J Wakeford C Quinn JB Evaluation of emtricitabine within a triple NRTI HAART regimen (abstract H-868). Presented at: 43rd Annual Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, September 14–17, 2003.

Staszewski S Keiser P Montaner J Raffi F Gathe J Brotas V Abacavir-lamivudine-zidovudine vs indinavir-lamivudine-zidovudine in antiretroviral-naïve HIV-infected adults: A randomized equivalence trial. JAMA 2001;285:1155–63.

Thompson RL Wright AJ. General principles of antimicrobial therapy. Mayo Clin Proc 1998;73:995–1006.

Shafer RW Smeaton LM Robbins GK De Gruttola V Snyder SW D'Aquila RT Comparison of four-drug regimens and pairs of sequential three-drug regimens as initial therapy for HIV-1 infection. N Engl J Med 2003;349:2304–15.